SCHEMBL2260905

SCHEMBL2260905

Cc1cc(C(OS(C)(=O)=O)(C(F)(F)F)C(F)(F)F)cc(C)c1NC(=O)c1cccc(NC(=O)c2cccc(Cl)c2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNK3 O14649 2/20 0.51
KCNK9 Q9NPC2 2/20 0.51
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
RXFP1 Q9HBX9 1/20 0.47
LMNA P02545 2/20 0.47
PTBP1 P26599 1/20 0.47
RHOC P08134 1/20 0.47
RHOA P61586 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
ADORA2A P29274 1/20 0.47
ADORA2B P29275 1/20 0.47
ADORA1 P30542 1/20 0.47
MAPT P10636 4/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
GAA P10253 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1813161 0.93 KCNK3 (0.52) KCNK3KCNK9NPC1RAB9ARXFP1
SCHEMBL1818337 0.90 MAPT (0.43) KCNK3KCNK9NPC1RAB9ALMNA
SCHEMBL1819533 0.89 KCNK3 (0.54) KCNK3KCNK9NPC1RAB9ARXFP1
SCHEMBL2258597 0.88 KCNK3 (0.49) KCNK3KCNK9NPC1RAB9ALMNA
SCHEMBL2259443 0.87 RAB9A (0.45) KCNK3KCNK9RAB9ARXFP1LMNA
SCHEMBL1818358 0.85 MEN1 (0.52) KCNK3KCNK9NPC1RAB9ARXFP1
SCHEMBL1812611 0.85 KMT2A (0.50) KCNK3KCNK9RAB9ARXFP1MAPT
SCHEMBL1822021 0.83 KCNK3 (0.57) KCNK3KCNK9NPC1RAB9ARXFP1
SCHEMBL2261615 0.82 BRAF (0.44) KCNK3KCNK9RXFP1ALDH1A1
SCHEMBL1812039 0.79 ALDH1A1 (0.51) NPC1RAB9ARXFP1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110201603-A1 Novel Acylaminobenzamide Derivatives BAYER CROPSCIENCE AG (DE) 2011-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201603-A1 Novel Acylaminobenzamide Derivatives KCNB1, KCNA5, KCNA7 KCNK3 174/4885KCNK9 461/4885NPC1 3104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.